hERG Screening Market to Reach USD 8.2 Billion by 2034 at 12.6% CAGR, Driven by Rising Cardiovascular Disease Burden and Advancements in Drug Safety Testing

The global hERG screening market is expanding as pharmaceutical and biotechnology companies increasingly prioritize cardiac safety assessment during drug discovery and development. Human Ether-à-go-go-Related Gene (hERG) screening is used to evaluate whether drug candidates block hERG potassium channels, which play an important role in cardiac electrical activity. Inhibition of these channels can prolong the QT interval and increase the risk of potentially life-threatening arrhythmias. Growing emphasis on drug safety evaluation and the development of innovative medicines is supporting demand for reliable hERG screening technologies.

The global hERG screening market was valued at US$ 2.2 billion in 2023 and is projected to reach US$ 8.2 billion by 2034, expanding at a compound annual growth rate (CAGR) of 12.6% from 2024 to 2034. Market growth is supported by the increasing burden of cardiovascular diseases, rising demand for preclinical safety testing, and the adoption of advanced electrophysiology and computational approaches for evaluating drug-induced cardiac risks.

Market participants are focusing on expanding screening capabilities, improving assay reliability, and strengthening collaborations with pharmaceutical companies and research organizations. Advances in in vitro electrophysiology, ion channel testing, and computational drug safety assessment are creating opportunities to improve the evaluation of potential cardiotoxicity during drug development.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86227

Market Introduction

The hERG screening market encompasses laboratory services, assays, and technologies used to evaluate the activity of the hERG potassium channel and identify compounds that may interfere with cardiac electrical function. The hERG channel is encoded by the KCNH2 gene and contributes to the repolarization phase of the cardiac action potential.

Drug candidates that inhibit hERG channel activity can delay cardiac repolarization and prolong the QT interval, potentially increasing the risk of arrhythmias. Consequently, hERG screening is an important component of nonclinical safety assessment and pharmaceutical research, particularly during the evaluation of potential drug-induced cardiac toxicity.

In vitro hERG patch-clamp assays are widely used to characterize ion channel activity and assess the effects of drug candidates on electrical currents. Other approaches, including radioligand-based assays and computational models, can support the evaluation of channel interactions and cardiac safety risks.

Pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic research institutions use hERG screening during drug discovery and preclinical development. These assessments help researchers identify potential safety concerns before advancing compounds into later stages of development.

The market includes screening based on gene type, ion channel characteristics, and application categories. Demand is influenced by pharmaceutical research activity, the need for reliable safety data, technological advances, and regulatory expectations concerning the evaluation of drug-induced QT prolongation.

Market Growth Drivers

Rising Incidence of Cardiovascular Diseases and Growing Focus on Cardiac Safety

The increasing burden of cardiovascular diseases is contributing to demand for cardiac research and drug safety assessment. Risk factors such as hypertension, diabetes, high cholesterol, and sedentary lifestyles are associated with cardiovascular complications and are increasing the need for effective treatments.

According to the World Health Organization, cardiovascular diseases account for approximately 17.9 million deaths annually, as reported in the supplied source. The substantial burden of these conditions highlights the importance of developing medicines that can address cardiovascular health needs while maintaining acceptable safety profiles.

Drug-induced cardiotoxicity is an important consideration in pharmaceutical development. Certain compounds can affect cardiac ion channels and interfere with the electrical activity of the heart. Screening for hERG channel inhibition helps researchers identify potential risks associated with QT interval prolongation and possible arrhythmias.

The need to evaluate cardiac safety extends across drug development programs, including those involving patients who may already have cardiovascular conditions or receive treatments associated with cardiac risks. Consequently, pharmaceutical and biotechnology companies are incorporating ion channel screening into their safety evaluation workflows.

As drug discovery activity continues and developers place greater emphasis on identifying safety concerns early, demand for hERG screening services and technologies is expected to increase.

Growing Number of Innovative Drug Development Programs and Safety Assessments

The expansion of pharmaceutical research and the development of innovative medicines are supporting demand for hERG screening. New drug candidates must undergo extensive evaluation to establish their pharmacological activity, potential toxicity, and suitability for further development.

Cardiac safety testing is particularly important because unintended effects on ion channels may create risks that are not apparent from a compound's intended therapeutic action. hERG screening enables researchers to assess whether a candidate interacts with the channel and determine whether additional investigations are required.

Regulatory guidance concerning the evaluation of QT/QTc interval prolongation and proarrhythmic potential has contributed to the importance of structured cardiac safety assessment. Screening technologies are also evolving to support more efficient testing and provide information that can be integrated with other preclinical safety findings.

In August 2023, Metrion Biosciences Limited announced that it had received notification from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) confirming its inclusion in the UK Good Laboratory Practice (GLP) Compliance Monitoring Programme. According to the supplied source, this enabled the company to provide GLP-compliant hERG ion channel screening services to the global life sciences community.

Such developments illustrate the role of specialized screening providers in supporting pharmaceutical research and the growing need for reliable testing services.

Market Trends and Opportunities

Advancements in Electrophysiology and High-Throughput Screening

Technological innovation is an important trend in the hERG screening market. Pharmaceutical developers require screening methods that can evaluate large numbers of drug candidates while providing reliable information about ion channel activity and potential cardiac safety concerns.

Patch-clamp electrophysiology remains an important technique for directly measuring ion channel function. Improvements in automated electrophysiology systems can support more standardized testing workflows and increase testing throughput, depending on the technology and assay configuration.

Radioligand-based assays provide another approach to studying interactions with ion channels. Different screening techniques offer varying levels of information, throughput, and experimental complexity, allowing researchers to select methods according to the stage of drug development and the objectives of the study.

The combination of screening technologies with broader preclinical safety assessment can help researchers evaluate potential risks more comprehensively. Continued improvements in assay design, data analysis, and laboratory automation are expected to create opportunities for specialized testing providers.

Growing Adoption of Computational and In Silico Cardiac Safety Assessment

Computational approaches are gaining attention as complementary tools for evaluating drug-induced cardiac risks. In silico methods use mathematical models and computational simulations to investigate how compounds may influence cardiac electrical activity.

These approaches can help researchers examine potential proarrhythmic effects and integrate information from multiple sources. When used alongside experimental methods, computational models may support the interpretation of screening results and provide additional insight into the potential cardiac effects of drug candidates.

In October 2022, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) issued updates to the S7B guideline and associated questions and answers concerning the clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential. The supplied source identifies these developments as supporting the use of human in silico drug trials as a tool for proarrhythmia risk assessment.

The growing integration of experimental and computational methods creates opportunities for companies offering combined cardiac safety assessment services. Wider adoption will depend on scientific validation, model reliability, appropriate interpretation, and alignment with applicable regulatory expectations.

Expansion of Contract Research and Specialized Screening Services

Pharmaceutical and biotechnology companies often work with specialized research organizations to access advanced screening technologies, technical expertise, and laboratory capabilities. Contract research organizations can support drug discovery programs by providing ion channel testing and other preclinical safety services.

Specialized providers can offer access to electrophysiology platforms and experienced research teams without requiring every pharmaceutical developer to establish equivalent capabilities internally. This model can be particularly relevant for organizations seeking flexible access to screening services across multiple drug development programs.

Collaborations between CROs, technology developers, and pharmaceutical companies can also support improvements in research workflows and data analysis. In March 2020, Charles River Laboratories formed an alliance with Deciphex to co-develop deep learning-enabled technologies intended to accelerate pathology analytics, according to the supplied source.

Although this collaboration focused on pathology analytics rather than specifically on hERG screening, it illustrates the broader use of technology partnerships to improve preclinical research processes.

Continued demand for specialized testing services is expected to create opportunities for providers that can deliver reliable results, appropriate quality standards, and capabilities suited to different drug discovery requirements.

Growing Emphasis on Regulatory Compliance and Early Risk Identification

Cardiac safety evaluation is an important consideration throughout pharmaceutical development. Identifying potential hERG channel inhibition early can help researchers determine whether a drug candidate requires further investigation, modification, or additional safety testing.

Regulatory expectations concerning the assessment of QT prolongation and proarrhythmic potential have encouraged the use of structured evaluation strategies. Screening providers must therefore focus on assay reliability, data quality, laboratory practices, and the suitability of their methods for intended research applications.

The inclusion of appropriate controls, standardized testing procedures, and complementary safety assessments can improve the interpretability of results. Providers offering validated methods and suitable documentation may be better positioned to serve pharmaceutical companies operating in regulated development environments.

These requirements create opportunities for laboratories investing in advanced screening platforms, quality systems, and specialized scientific expertise.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86227

Regional Outlook

North America

North America dominated the global hERG screening market in 2023, according to the supplied source, and is expected to maintain its leading position during the forecast period. Regional demand is supported by cardiovascular disease burden, pharmaceutical research activity, and the presence of biotechnology companies and specialized research organizations.

The United States is a major contributor to regional demand for cardiac safety assessment. The supplied source cites American College of Cardiology data indicating that a myocardial infarction occurs approximately every 40 seconds in the United States. It also reports that 356,460 Americans experienced out-of-hospital cardiac arrest in 2017, with emergency medical services called for 52% of cases.

These figures illustrate the substantial burden of cardiac conditions, although disease incidence alone does not determine demand for hERG screening. Pharmaceutical research investment, drug development pipelines, laboratory capabilities, and safety evaluation requirements are also important market factors.

Canada contributes to the regional market through healthcare research and pharmaceutical development activities. Continued demand for preclinical testing and advanced cardiac safety assessment is expected to support North America's position.

Europe

Europe represents an important market for hERG screening, supported by pharmaceutical research, established life sciences infrastructure, and demand for preclinical safety testing. Germany and the United Kingdom are identified in the supplied source as leading contributors to regional demand.

The United Kingdom's pharmaceutical research ecosystem includes specialized screening providers such as Metrion Biosciences Limited. Its reported inclusion in the UK GLP Compliance Monitoring Programme in 2023 illustrates the role of laboratory quality standards in supporting the provision of specialized research services.

Germany also contributes to regional pharmaceutical and biotechnology research. Demand across Europe is influenced by drug discovery investment, the availability of specialized laboratories, and the need to assess cardiac safety during pharmaceutical development.

Asia Pacific

Asia Pacific's hERG screening market is supported by pharmaceutical research activity and the growing life sciences sectors in countries such as China and India. These markets are identified in the supplied source as important contributors to the region's cardiac safety screening landscape.

Expansion of pharmaceutical manufacturing, biotechnology research, and contract research capabilities can create opportunities for specialized screening providers. Greater access to advanced laboratory technologies and increasing participation in drug discovery programs may also support demand.

Japan, Australia, and New Zealand are included in the market's geographic coverage. Regional growth will depend on research investment, laboratory infrastructure, regulatory requirements, and access to qualified testing services.

Latin America

Latin America offers opportunities for hERG screening providers as pharmaceutical research capabilities and demand for specialized laboratory services develop. Brazil and Mexico are among the countries included in the market's geographic coverage.

Market development will depend on pharmaceutical research investment, access to advanced testing technologies, collaborations with international research organizations, and the availability of specialized scientific expertise.

Middle East & Africa

The Middle East & Africa region presents potential opportunities through the development of healthcare research capabilities and increased participation in pharmaceutical and biotechnology activities. South Africa and GCC countries are included in the supplied market coverage.

Growth will depend on investment in laboratory infrastructure, access to advanced testing services, partnerships with established research organizations, and the development of local life sciences capabilities.

Market Segmentation

The hERG screening market can be segmented by type, ion channel, application, and region.

By type, the market includes Gene KCNH2 and Mutant KCNH2. These categories relate to the hERG channel and its genetic variants, which are relevant to studies examining ion channel function and the effects of compounds on cardiac electrical activity.

By ion channel, the market is classified into voltage-gated and ligand-gated categories, as specified in the supplied market segmentation. These categories reflect the channel classifications used in the source's market framework.

By application, the market includes antiarrhythmic, antipsychotic, antibiotics, and other drug categories. hERG screening can support the evaluation of cardiac safety risks associated with drug candidates across therapeutic areas.

Regional coverage includes North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Country-level coverage includes the United States, Canada, Germany, the United Kingdom, France, Italy, Spain, China, India, Japan, Australia and New Zealand, Brazil, Mexico, South Africa, and GCC countries.

Competitive Landscape

The global hERG screening market includes pharmaceutical companies, specialized ion channel testing providers, biotechnology research organizations, and contract research laboratories. Key companies identified in the supplied source include Abcam Limited, ABR-Affinity BioReagents, Inc., AstraZeneca plc, Aureus Sciences, AVIVA Biosciences, Cambridge Biosciences, ChanTest Corporation, Charles River Laboratories, and Chemaxon.

Competition is influenced by assay reliability, screening throughput, scientific expertise, laboratory quality standards, and the ability to support pharmaceutical development programs. Providers offering electrophysiology testing, ion channel assays, and complementary cardiac safety assessment services can serve different research requirements.

Companies are also pursuing collaborations and technology partnerships to expand their capabilities and improve research efficiency. In March 2020, Charles River Laboratories partnered with Deciphex to co-develop deep learning-enabled technologies for pathology analytics. While the initiative was not specifically a hERG screening product launch, it demonstrates the use of technology collaborations to strengthen preclinical research capabilities.

Market participants may also seek opportunities to expand geographic reach and develop relationships with pharmaceutical companies, biotechnology firms, and research institutions. The ability to provide dependable testing services and appropriate scientific documentation is expected to remain important to competitiveness.

Market Outlook

The global hERG screening market is projected to increase from US$ 2.2 billion in 2023 to US$ 8.2 billion by 2034, registering a CAGR of 12.6% during 2024–2034. Rising cardiovascular disease burden, expanding pharmaceutical research, and the need to identify drug-induced cardiac risks are expected to support market growth.

North America led the market in 2023, while Europe and Asia Pacific offer opportunities through pharmaceutical research, specialized laboratory services, and the expansion of drug discovery activities. Advances in electrophysiology, high-throughput screening, and computational cardiac safety assessment are creating additional opportunities for testing providers.

Although assay selection, laboratory quality, scientific validation, and the interpretation of screening results remain important considerations, continued emphasis on preclinical cardiac safety is expected to support demand for hERG screening services and technologies through 2034.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=86227<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Bone Wax Market

Internet of Medical Things Market

AI-Powered Healthcare Market

Value-Based Healthcare Solutions Market

Medical Billing Outsourcing Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com